taken relatively infrequently, little is known about 1) the actual rates of adoption for specific indications, 2) patient and provider characteristics, and 3) implications for procedural safety or outcomes. To better inform clinicians and researchers about current practice patterns, as well as potential differences in procedural safety and outcomes, large-sample studies are necessary. To this end, we examined the Nationwide Inpatient Sample (NIS), an all-payer, nonfederal hospital discharge database, to trend and compare DBS for FDA-approved, HDE, and emerging indications from 2002 through 2011.
methods patient population
Data were collected from the NIS (Healthcare Cost and Utilization Project [HCUP] , Agency for Healthcare Research and Quality), 56 a stratified sample of all patient discharges from approximately 20% of nonfederal hospitals in the United States from 2002 to 2011. Each discharge in the data set is weighted by HCUP to extrapolate the total annual patient discharge information. Discharges utilizing DBS were identified using ICD-9 procedure code 02.93 (implantation or replacement of intracranial neurostimulator lead [s] ). All primary diagnosis codes were then reviewed and categorized into 1 of 14 diagnostic groups. For further analysis, primary PD and ET were categorized as FDA approved, dystonia and OCD were categorized as HDE, and all other diagnoses were categorized as emerging. The epilepsy diagnosis codes were excluded because it was not possible to distinguish between DBS implants and other electrode implants. Procedures with no associated primary diagnosis code and codes not corresponding to any published indication were excluded.
We combined data from the NIS with the Area Resource File (ARF), 49 a basic county-specific database containing more than 6000 socioeconomic and environmental variables for each of the nation's counties. ARF provides data detailing the number of neurologists and neurosurgeons by county, among other variables. We linked the most recent ARF file (2011) (2012) by the county Federal Information Processing Standard code to the NIS discharge data in accordance with a previously described method. 41 This approach allowed the most recent and extensive information regarding neurologist and neurosurgeon density (2010) to be matched to the NIS dataset (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) . The relative neurologist and neurosurgeon county-wide densities did not significantly fluctuate across different years within ARF (range of average density 4.29-4.74 neurologists/100,000 individuals and 1.66-1.76 neurosurgeons/100,000 individuals; p = 0.69 and p = 0.84, respectively; 2-tailed t-test).
patient characteristics
The ICD-9 primary diagnosis code, age, sex, modified comorbidity score, race, income quartile of the patient's ZIP code, and form of payment for hospital admission were extracted from the NIS database. NIS provides data for the primary and secondary payers for each patient discharge. We combined both categories of payers into 1 of 4 mutually exclusive categories: "private insurance," "Medicaid without private insurance," "Medicare with neither private insurance nor Medicaid," and "other." NIS provides 6 categories for race/ethnicity: "White," "Black," "Hispanic," "Asian/Pacific Islander," "Native American," and "Other." Medical comorbidities were defined using a modified version of the Elixhauser Comorbidity Index.
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This score is an assessment of the general comorbidity associated with a given patient, which includes a set of 30 comorbidity markers. We used a previously described 12 modification of the score, which excluded 2 neurological comorbidity variables-"other neurological deficit" and "paralysis"-so the highest possible comorbidity score was 28.
hospital characteristics
Hospital bedsize (small, medium, large), region (Northeast, Midwest, South, West), setting (urban or rural), teaching hospital status, experience (number of discharges by the hospital for ICD-9 procedure code 02.93), and densities of neurologists and neurological surgeons by hospital county were identified in the ARF and NIS databases.
Outcomes
We examined 5 outcomes: complications, mortality, discharge disposition, length of stay (LOS), and hospital charges. We identified a number of potential complications resulting from DBS surgery, including hematoma, hemorrhage, and infarction (997.00-997.09 and 998.1-998. 13 The presence of any of these complications was included as an outcome variable we created called "any complication." We report discharge disposition by individual destination and non-home discharges, which is a sum of the short-term hospital transfers, other transfers (including skilled nursing facilities), and death. In addition to LOS, we examined the date of the primary procedure relative to admission in order to isolate group differences in postoperative LOS. Total charges were adjusted based on LOS in order to determine the charges per day.
Statistical analyses
The univariate analyses used the Mann-Whitney U-tests and chi-square tests using built-in and custom MATLAB scripts (MathWorks). Hierarchical regression models (SAS procedure GLIMMIX and MIXED; SAS Institute) were used to analyze the variables that predicted outcomes. Predictor variables included age, sex, modified comorbidity score, the presence of any complication, race, income quartile of the patient's zip code, payer status, hospital's level of experience, hospital bedsize, region, setting (urban or rural), teaching status, year of discharge, and type of DBS indication (approved or emerging). Complete case analysis was used. The unique hospital identification code served as the nesting variable, and p value < 0.05 was considered statistically significant. Bonferroni correction for multiple comparisons was used as appropriate. Statistics are reported by sample mean ± standard error of the mean.
results

Volume of dBS Surgery
From 2002 to 2011, there were an estimated 1648 discharges for HDE indications and 2014 discharges for emerging indications that received DBS at nonfederal hospitals in the United States. During the same time period, there were 30,490 discharges for FDA-approved indications. Table 1 provides the estimated number of discharges for each primary diagnosis group and the associated ICD-9 primary diagnosis codes. Figure 1 shows the discharges by year from 2002 to 2011 for approved and HDE/emerging indications. The volume of DBS surgeries grew rapidly for HDE and emerging indications, with a combined least-squares fitted average annual rate of growth of 36.1% in comparison with 7.0% for PD and ET.
patient characteristics
Patients undergoing DBS for HDE and emerging indications were, on average, younger (41.2 ± 1.1 and 52.1 ± 0.9 vs 64.3 ± 0.2 years of age, respectively; p < 0.0001) with lower modified comorbidity scores (0.65 ± 0.05 and 0.84 ± 0.05 vs 0.97 ± 0.01, respectively; p < 0.0001) in comparison with those with FDA-approved indications (Table 2 ). They were also more likely to be female and either black or Hispanic. There was no significant difference in patient income between groups.
The average age for each emerging indication was younger than that for either PD (63.8 ± 0.2 years) or ET (65.9 ± 0.4 years). The youngest patients were those undergoing DBS for Tourette syndrome and other tic disorders (31.3 ± 2.4 years), dystonia (41.1 ± 1.1 years), multiple sclerosis (44.9 ± 1.9 years), or OCD (45.8 ± 4.9 years). The oldest were those with the late effects of cerebrovascular disease (57.7 ± 2.6 years) and other movement disorders (57.0 ± 1.4 years). Table 2 shows the differences in hospital characteristics between DBS patients for FDA-approved, HDE, or emerging indications. DBS for HDE indications was performed at hospitals with higher annual DBS caseloads (54.5 ± 1.8) in comparison with both FDA-approved (41.8 ± 0.4) and emerging indications (39.5 ± 1.6) (p < 0.0001). The overall DBS caseloads were highest at hospitals that performed DBS for OCD (82.3 ± 20.5), depression (60.1 ± 14.3), and dystonia (53.6 ± 1.8). Of note, caseloads were significantly below average at hospitals that performed DBS for the late effects of cerebrovascular disease (27.9 ± 3.3) and pain (33.1 ± 3.0).
hospital characteristics
HDE and emerging indications were both treated at hospitals with higher county densities of neurologists and neurosurgeons. DBS is performed largely at teaching hospitals for FDA-approved (87.3%), HDE (94.3%), and emerging indications (90.7%). Table 2 demonstrates the discharge outcomes for the comparison groups. By the univariate analysis, patients undergoing DBS for HDE and emerging indications had notably higher reported rates of any complication (6.0% and 5.6% vs 3.4%; p < 0.001), and in the multivariate analysis HDE indication was independently associated with complications (OR 2.12; 95% CI 1.10-4.09; p = 0.02) ( Table 3 ). The only other independent predictor of complications was an increased comorbidity score. Of note, no hospital characteristics were protective against complications in this analysis.
complications and discharge disposition
The higher reported complication rates for HDE and emerging indications (6.0% and 5.6%, respectively) in comparison with FDA-approved indications (3.4%) was driven by the higher rates of hematoma, hemorrhage, or infarction (3.3% and 1.6% vs 1.1%), mechanical complications (0.6% and 0.7% vs 0.3%), and lead removal on the same admission (0.0% and 1.9% vs 0.3%). The rates of any complication were highest for pain (8.5%), late complications of cerebrovascular disease (6.2%), dystonia (6.2%), and other movement disorders (5.7%). The high complication rates for pain and cerebrovascular disease were driven largely by lead removal (3.4% and 6.2%, respectively). Dystonia patients had notably high reported rates of hemorrhage or infarction (3.3%), mechanical complications (0.6%), and infections during admission (0.4%).
HDE indications had lower rates of non-home discharge (3.5%) in comparison with both emerging and FDA-approved indications (6.8% and 6.0%, respectively), and emerging indications were independently associated with non-home discharge in the multivariate model (OR 1.77; 95% CI 1.06-2.96; p = 0.03) ( Table 3 ). Other independent risk factors for non-home discharges included increased age, higher comorbidity score, Hispanic ethnicity, insurance under Medicare, and any complications (Table  3) . A higher hospital caseload was weakly associated with fewer non-home discharges (OR 0.99 per 1 case; 95% CI 0.98-0.998; p < 0.0082).
lOS and total charges
Those patients undergoing DBS for HDE and emerging indications had longer postprocedure LOS (2.2 and 2.6 vs 1.8 days; p < 0.0001), and an emerging indication was an independent risk factor for increased LOS in the multivariate analysis (+10.6%; 95% CI 7.6%-13.6%; p < 0.0001). The occurrence of any complication was strongly associated with increased LOS (+46.7%; 95% CI 42.2%-51.4%; p < 0.0001). Patient characteristics that increased the LOS included age (+0.09% per year; 95% CI 0.04-0.15%; p = 0.0011) and comorbidity score (+1.4% per point; 95%CI 0.8%-2.0%; p ≤ 0.0001). Male sex was weakly protective (-2.0%; 95% CI -3.2 to -0.8%; p = 0.0011). Northeastern and Midwestern hospitals demonstrated increased LOS (+10.8%; 95% CI 3.4%-18.6%, p < 0.0034; and +10.3%; 95% CI 3.2%-17.9%, p = 0.0038, respectively).
Total hospital charges were significantly higher for HDE and emerging indications ($88,173 ± $3557 and $78,523 ± $2742, respectively) than for FDA-approved indications ($62,077 ± $508; p < 0.0001). The difference was driven almost entirely by the LOS, as there was no significant difference in the charges per day. discussion DBS for HDE and emerging indications has grown rapidly over the last decade as the procedure has been adopted to treat a wide array of diseases. The hospitals leading the charge tended to have more neurosurgeons and neurologists locally, but were not necessarily those with the most DBS experience. Patients were on average younger and healthier but had a higher rate of reported complications, longer mean LOS, and greater total charges than those treated for PD or ED.
rapid growth of hde and emerging indications
This study quantifies the rate of adoption of DBS for new indications in a cross-section of nationwide discharges. Improved understanding of brain networks and their dysfunction in neurological and psychiatric disease has led to numerous new targets for DBS and a tide of reports, largely from academic medical centers. 20, 24 As the results demonstrate, this enthusiasm has led to significant rates of adoption nationally for a number of disorders.
The most popular new indications included dystonia and other movement disorders, pain, the late effects of cerebrovascular disease, multiple sclerosis, tics, and depression. Not surprisingly, the greatest growth has occurred in DBS for dystonia, which received HDE status in 2003 and has been shown to be effective in numerous non-FDA application trials. [27] [28] [29] 31, 32, 45, 59, 60 The next largest category-other movement disorders-represents a heterogenous group of conditions, many with similar phenotypes to primary PD, ET, and primary dystonia, but were not included in the original device approvals or HDE. 40 These are technically investigational or off-label indications that have not met the standards of evidence required by the FDA, but may share similar therapeutic targets and mechanisms of the action. Those patients with primary diagnoses of "cerebrovascular disease (late effects)" and multiple sclerosis could have been treated for either pain or movement disorder symptoms, as both have been reported, 25, 47, 55 although * The results of our multivariate model were used to evaluate predictors of complications, non-home discharges, and LOS.
the prevalence of these indications was surprising given the limited case reports in the literature. The NIS query also captured small numbers of most other indications that have been reported in the literature, largely in the context of pilot studies and ongoing trials, including OCD, Alzheimer's disease, conduct disorder, obesity, and tinnitus. The rarity of these cases makes the extrapolation to national estimates more subject to sampling error, as a few centers performing these procedures but not captured in the NIS data set could change the estimates significantly. Notable reported indications not captured in the data set include anorexia, 34 substance addiction, 42 and dementia or cognitive decline. 19, 33 
high-Volume teaching hospitals
Overall, the DBS caseloads were highest at hospitals that performed DBS for OCD, depression, and dystonia, suggesting that the most experienced centers are leading the adoption of HDE and investigational indications. It is somewhat concerning, however, that DBS is being performed at lower-than-average volume centers for other indications such as pain and the late effects of cerebrovascular disease. This finding would suggest an unexpected trend of off-label DBS at less experienced centers. Historical results suggest that the surgical caseload is particularly important during the early development of a procedure. The shortage of larger studies on emerging indications argues for better data collection through either centralization at high-volume centers or registries.
Younger and healthier patients
The finding that patients with emerging indications were younger with below average comorbidity scores is confounded by the variation in diseases being treated, but may reflect a bias in patient selection as new indications are adopted. The younger and healthier patient population may partially reflect the earlier onset of diseases with emerging indications in comparison with PD and ET, which tend to affect the elderly. Dystonia, tics, multiple sclerosis, OCD, and depression tend to have earlier onsets. However, even the oldest, new patient populations undergoing DBS-those with other movement disorders and the late effects of cerebrovascular disease-were, on average, younger than the PD and ET patients. It is not surprising that surgeons would select younger and healthier candidates for new or experimental operations. Historically, the average age of PD and ET patients undergoing DBS has been increasing since its introduction, 12, 39 as has been the case for numerous other surgical procedures, as techniques become refined and risks are reduced. 16, 23, 54 When evaluating early outcomes data on using DBS for new indications, the possibility of selection bias should be taken into consideration.
higher reported complication rates
The higher reported complication rates with DBS for HDE and emerging indications may reflect reporting bias, with closer scrutiny applied to these emerging indications, perhaps in the setting of closely monitored studies. However, certain findings nonetheless warrant further attention.
The higher reported rates of hemorrhage or infarction for HDE and emerging indications may reflect reporting bias, but the rate was notably higher for dystonia (3.3%) than any other indication. A higher hemorrhage rate could plausibly reflect greater risk targeting the globus pallidus (the most common target in dystonia), less familiarity with new targets and trajectories, or some unmeasured or unknown associated risk factors in these patients.
Higher rates of lead removal also contributed to the elevated reported complication rate for emerging indications. Removal on the same admission as implantation was particularly high following DBS for pain and the sequelae of cerebrovascular disease. This difference likely reflects stimulation trials and elective removal due to the lack of efficacy or untoward stimulation effects.
increased lOS for New indications
Patients undergoing DBS for HDE and emerging indications had longer postprocedure LOS (2.2 and 2.6 vs 1.8 days; p < 0.0001), and emerging indication was an independent risk factor for increased LOS in the multivariate analysis. The underlying diseases may themselves be more complex, and postoperative management in these patients may require longer hospitalizations. However, longer LOS may also represent a learning curve or increased precaution in the management of patients with less familiar diseases or a relatively new intervention. Such precautions may be appropriate as neurosurgeons learn to manage new types of postoperative sequelae and observe patients over a slightly longer duration in order to determine the efficacy or side effects of microlesion or stimulation. Based on the experiences with PD and ET over the last decade, it is reasonable to anticipate that LOS will decrease over time as surgical and patient management techniques are refined.
In the interim, it should be anticipated that treating new patient populations will necessarily carry additional costs, and this cost burden should be taken into consideration when seeking reimbursement or research funding.
Future trends
There is reason to anticipate that the higher reported complication rate, to the extent that it reflects reality, and increased LOS seen in the HDE and emerging indications groups will reduce with time. Prior studies 12, 39 demonstrate that over the last 2 decades the short-term outcomes of DBS for PD and ET have been improving. In our multivariate model, each progressive year in the study period was independently associated with fewer non-home discharges and shorter LOS.
limitations
In addition to the limitations of the conclusions discussed above, there are several general limitations to the NIS data set that could have affected the categorization and analysis of the DBS cases based on the indications. First, there is no guarantee that the primary diagnosis code was the indication for surgery. All primary diagnosis codes were considered, and only those related to plausible indications were included. Additionally, NIS is a discharge-level data set without unique patient identifiers, and therefore procedures that were staged across multiple discharges and reimplantations could have been counted more than once. Finally, due to the limitations of the data set, this study did not attempt to look at the outcomes beyond the point of discharge or efficacy of DBS for the various indications.
conclusions
DBS for HDE and emerging indications has grown rapidly in the last decade. While dystonia, OCD, and depression are primarily being adopted at high-volume centers, there is a concerning pattern of off-label use at less experienced hospitals. Patients undergoing DBS for HDE and emerging indications tend to be younger and healthier than the larger PD and ET populations, possibly reflecting a selection bias that should be taken into consideration when evaluating early results. The higher reported complication rates in the HDE and emerging indications populations may reflect reporting bias, but a higher rate of hemorrhage in dystonia patients specifically warrants further attention. Finally, additional LOS and costs should be anticipated as new indications are adopted.
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